Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan

Annals of the Rheumatic Diseases

Volumn 65, Issue 12, 2006, Pages 1661-1663

  Yamada, T ^a   Nakajima, A ^a   Inoue, E ^a   Tanaka, E ^a   Hara, M ^a   Tomatsu, T ^a   Kamatani, N ^a   Yamanaka, H ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAMNESIS; ARTICLE; CONTROLLED STUDY; DATA BASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; JAPAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SELF REPORT; TUBERCULOSIS;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751274843     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.047274     Document Type: Article

References (14)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
2. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Frust D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
3. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.
4. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safely. J Rheumatol 2002;29(Suppl 65):33-8.
5. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
6. Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 2000. Atlanta, GA: US Department of Health and Human Services, CDC, 2001.
7. World Health Organisation. Global tuberculosis control, WHO Report. Geneva: WHO, 2003:171.
8. Sociedad Espanola de Salud Publica (SESPAS). 2002 SESPAS report: investing in health. In: Cabases JM, Vilalbi JR, Aibar C, eds. Priorities for public health in Spain. Granada, Spain: Escuela Andaluza de Salud Publica, 2002:21-42.
9. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
10. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92.
11. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
12. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montera MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
13. Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infecf Dis Clin North Am 2001;25:1900-7.
14. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.